167 related articles for article (PubMed ID: 2639634)
1. Transplantable mouse 16/c mammary adenocarcinoma as a model in experimental cancer therapy. II. Modification of tumor-host interactions by therapeutic procedures.
Rak J; Strzadała L; Kuśnierczyk H; Radzikowski C
Arch Immunol Ther Exp (Warsz); 1989; 37(3-4):379-88. PubMed ID: 2639634
[TBL] [Abstract][Full Text] [Related]
2. Transplantable mouse mammary adenocarcinoma 16/c as a model in experimental cancer therapy. III. Sensitivity to antitumor drugs.
Rak J; Kuśnierczyk H; Strzadała L; Kłosiewicz S; Radzikowski C
Arch Immunol Ther Exp (Warsz); 1989; 37(3-4):389-97. PubMed ID: 2639635
[TBL] [Abstract][Full Text] [Related]
3. [A murine model of mammary adenocarcinoma (VI TA2MA-891) with high rate of spontaneous metastases in the lungs].
Gao P; Su Y; Gao Y
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1994 Apr; 16(2):147-52. PubMed ID: 7527302
[TBL] [Abstract][Full Text] [Related]
4. Antitumor activity of platinum(II) complexes with histamine and radioiodinated histamine in a transplantable murine adenocarcinoma model.
Garnuszek P; Karczmarczyk U; Maurin M
Nucl Med Biol; 2008 Jul; 35(5):605-13. PubMed ID: 18589305
[TBL] [Abstract][Full Text] [Related]
5. Genistein alone or combined with cyclophosphamide may stimulate 16/C transplantable mouse mammary cancer growth.
Wietrzyk J; Mazurkiewicz M; Madej J; Dzimira S; Grynkiewicz G; Radzikowski C; Opolski A
Med Sci Monit; 2004 Nov; 10(11):BR414-9. PubMed ID: 15507846
[TBL] [Abstract][Full Text] [Related]
6. Biology and therapeutic response of a mouse mammary adenocarcinoma (16/C) and its potential as a model for surgical adjuvant chemotherapy.
Corbett TH; Griswold DP; Roberts BJ; Peckham JC; Schabel FM
Cancer Treat Rep; 1978 Oct; 62(10):1471-88. PubMed ID: 709550
[TBL] [Abstract][Full Text] [Related]
7. Transplantable mouse 16/C mammary adenocarcinoma as a model in experimental cancer therapy. I. Kinetics of growth and spread.
Rak J; Kuśnierczyk H; Strzadała L; Radzikowski C
Arch Immunol Ther Exp (Warsz); 1988; 36(3):325-34. PubMed ID: 3250355
[TBL] [Abstract][Full Text] [Related]
8. The antitumor effect of postoperative treatment with genistein alone or combined with cyclophosphamide in mice bearing transplantable tumors.
Wietrzyk J; Opolski A; Madej J; Radzikowski C
Acta Pol Pharm; 2000 Nov; 57 Suppl():5-8. PubMed ID: 11293263
[TBL] [Abstract][Full Text] [Related]
9. Potential of the aminosterol, squalamine in combination therapy in the rat 13,762 mammary carcinoma and the murine Lewis lung carcinoma.
Teicher BA; Williams JI; Takeuchi H; Ara G; Herbst RS; Buxton D
Anticancer Res; 1998; 18(4A):2567-73. PubMed ID: 9703911
[TBL] [Abstract][Full Text] [Related]
10. [Inhibitory effect of UFT on postoperative lung metastasis of mammary adenocarcinoma in SHR rats].
Komatsumoto M; Li S; Hamada J; Takeichi N; Hosokawa M; Okayasu T; Tanabe T; Kobayashi H
Gan To Kagaku Ryoho; 1988 May; 15(5):1739-45. PubMed ID: 3130810
[TBL] [Abstract][Full Text] [Related]
11. Effect of hydroxyurea on growth of a transplantable mouse mammary adenocarcinoma.
Lerner LJ; Bianchi A; Dzelzkalns M
Cancer Res; 1966 Nov; 26(11):2297-300. PubMed ID: 5956633
[No Abstract] [Full Text] [Related]
12. Heterogeneity in drug sensitivity among tumor cell subpopulations of a single mammary tumor.
Heppner GH; Dexter DL; DeNucci T; Miller FR; Calabresi P
Cancer Res; 1978 Nov; 38(11 Pt 1):3758-63. PubMed ID: 698935
[TBL] [Abstract][Full Text] [Related]
13. Characterization of a slow-growing, transplantable rat mammary tumor (MCR-83): a model for endocrine-related cell kinetic studies.
van Dierendonck JH; Cornelisse CJ; van der Linden PW; van Putten LM; van de Velde CJ
Cancer Res; 1987 Aug; 47(15):4093-8. PubMed ID: 3607751
[TBL] [Abstract][Full Text] [Related]
14. [Changes in the content and composition of gangliosides of tumors as affected by chemotherapeutic agents].
Kozlov AM; Novikov AM; Bassalyk LS; Sof'ina ZP
Eksp Onkol; 1984; 6(5):62-6. PubMed ID: 6510346
[TBL] [Abstract][Full Text] [Related]
15. Pre-, peri-, and postoperative chemotherapy for breast cancer: is one better than the other?
Murthy MS; Scanlon EF; Reid SE; Yang XF
J Surg Oncol; 1996 Apr; 61(4):273-7. PubMed ID: 8627997
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of the incidence of metastasis in tumor-resected mice. Influence of soluble tumor extract and splenectomy.
Klein S; de Bonaparte YP; de D'Elia I
Invasion Metastasis; 1985; 5(5):309-16. PubMed ID: 4030247
[TBL] [Abstract][Full Text] [Related]
17. Acute in vivo resistance in high-dose therapy.
Teicher BA; Ara G; Keyes SR; Herbst RS; Frei E
Clin Cancer Res; 1998 Feb; 4(2):483-91. PubMed ID: 9516940
[TBL] [Abstract][Full Text] [Related]
18. Biophysical aspects of the integrated combination of cytostatic drugs with radiotherapy. Part 3: In vivo investigations on murine C3H mammary adenocarcinoma treated with cis-platinum, adriamycin, epirubicin, activated cyclophosphamide, activated isophosphamide and irradiation with 10 MeV electrons--verification of the therapeutic results with 31P-NMR spectroscopy.
Ulmer W
Strahlenther Onkol; 1991 Sep; 167(9):553-60. PubMed ID: 1925940
[TBL] [Abstract][Full Text] [Related]
19. Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastases.
Fisher B; Gunduz N; Saffer EA
Cancer Res; 1983 Apr; 43(4):1488-92. PubMed ID: 6831397
[TBL] [Abstract][Full Text] [Related]
20. [Influence of cyclophosphamide, ribo-azauracil and mercaleukin pretreatment on experimental metastasizing in a syngenic tumor-host system. I. Spontaneous breast carcinoma of the mouse].
Nowak C; Elbe B; Arnold W; Bender E
Arch Geschwulstforsch; 1973; 41(1):1-11. PubMed ID: 4700692
[No Abstract] [Full Text] [Related]
[Next] [New Search]
